

Neurocrine Biosciences to Participate at Investor Conferences in December

November 26, 2024

The 7th Annual Evercore HealthCONx Conference on December 3

Citi's 2024 Global Healthcare Conference on December 4

SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in December. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Vice-President of Investor Relations Todd Tushla will present at:



- The 7th Annual Evercore HealthCONx Conference at 10:50 a.m. Eastern Time on Tuesday December 3, 2024 in Coral Gables, Florida.
- Citi's 2024 Global Healthcare Conference at 1:45 p.m. Eastern Time on Wednesday December 4, 2024 in Miami.

The live presentations will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at <u>www.neurocrine.com</u>. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit <u>neurocrine.com</u>, and follow the company on <u>LinkedIn</u>, <u>X</u> (Formerly Twitter) and <u>Facebook</u>. (**in collaboration with AbbVie*)

NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.

C View original content to download multimedia: https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-investor-conferences-in-december-302316899.html

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc., Tony Jewell (Media), 858-617-7578, media@neurocrine.com; Todd Tushla (Investors), 858-617-7143, ir@neurocrine.com